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1Preeclampsia is a multisystemic disorder of pregnancy char-acterized by high blood pressure at or after 20 weeks of 
gestation accompanied by and/or proteinuria, acute kidney in-
jury, liver dysfunction, or fetal growth restriction.1 It affects 
>8 million pregnancies worldwide annually and is the leading 
cause of maternal death.2 Despite extensive research, the exact 
pathophysiological mechanisms underlying this syndrome re-
main poorly elucidated. Nonetheless, defective placentation 
is strongly considered to be a critical event in the pathology 
of the disorder.2 Failure to remodel spiral arteries results in 
high-pressure blood flow–mediated placental damage and in-
termittent fluctuations in oxygen delivery, which exposes the 
placenta to oxidative stress.3 The resultant placental ischemic 
microenvironment is inherently linked to increased production 
and secretion of deleterious soluble mediators that provoke 
extensive maternal inflammation and endothelial dysfunc-
tion.4 Several reports have observed higher levels of markers 
of oxidative stress (including F2-isoprostanes, nitrotyrosine, 
and 4-hydroxynonenal staining) in placental tissue from pre-
eclamptic pregnancies compared with those from uncompli-
cated pregnancies.5–8
While there are a number of different cellular sources of 
reactive oxygen species (ROS), mitochondria are the major 
cellular producers.9 Furthermore, in terms of preeclampsia, 
there is growing evidence incriminating mitochondrial dys-
function in its underlying pathophysiology.10 Initial stud-
ies showed increased mitochondrial lipid peroxidation and 
enhanced susceptibility to oxidative damage in placental 
tissue of pregnancies complicated by preeclampsia.11 More 
recently, work has confirmed this association with strong evi-
dence of perturbation of mitochondrial function in the metab-
olite profile of plasma samples taken at 15 weeks of gestation 
from patients who subsequently developed preeclampsia.12
While there is significant evidence for the pathogenic role 
of oxidative stress in the development of preeclampsia, clin-
ical trials of antioxidant interventions were disappointing and 
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not clinically effective in treating the disorder. One plausible 
explanation is that these antioxidants missed the intracellular 
location of ROS production, namely the mitochondria; hence 
they have failed to alleviate the pathological oxidative dam-
age. Another is that molecules such as L-ascorbate can actually 
be pro-oxidant in the presence of free iron.9 L-ergothioneine 
(ERG) is an unusual thiohistidine betaine amino acid and is a 
naturally occurring antioxidant discovered over a century ago 
in the rye ergot.13–16 The predominant role of ERG, via a va-
riety of mechanisms, is to serve as an antioxidant and cellular 
protectant against various kinds of ROS.17 Additionally, there 
has been some circumstantial evidence that ERG could target 
mitochondria18 and hence could dampen exaggerated mito-
chondria-specific ROS (mROS) in response to oxidative stress.
Therefore, we aimed to investigate the role of ERG as a 
potential therapeutic target for preeclampsia using the reduced 
uterine perfusion pressure (RUPP) model in pregnant rats. The 
placental ischemic RUPP model has numerous features of pre-
eclampsia that are clinically evident in women and has been 
used as a preclinical model for the investigation of novel thera-
peutic targets for the treatment of preeclampsia.19,20 Moreover, 
we additionally wanted to examine whether ERG ameliorated 
the clinical characteristics of preeclampsia, in part, via reg-
ulation of mROS production. To this end, we used a novel 
ratiometric mass spectrometry probe MitoB that specifically 
accumulates in mitochondria and generates a MitoP phenol 
product on reaction with H2O2, which can subsequently be 
analyzed ex vivo by mass spectrometry.
Materials and Methods
The techniques and data that support the findings of this study are 
available from the corresponding author on reasonable request.
Animals
Sprague Dawley-timed pregnant rats were supplied and maintained 
by the University College Cork Biological Services Unit. Animals 
were maintained at a temperature of 21°C, with a 12-hour light/
dark cycle and free access to food and tap water. All the proce-
dures were performed in accordance with the National Guidelines 
and the European Directive 2010/63/EU, under an authorization 
issued by the Health Products Regulatory Authority Ireland and 
approved by the Animal Ethics Committee of University College 
Cork (AE19130/P037).
RUPP Procedure
The RUPP procedure is a well-established surgical model for study-
ing the link between placental ischemia and hypertension in the preg-
nant rat and has been previously described in detail.19,21 In brief, on 
gestational day (GD) 14, under isoflurane anesthesia, RUPP reduc-
tion in blood flow to the uteroplacental unit was achieved by plac-
ing a silver clip (0.2 mm ID) on the abdominal aorta (1 clip) above 
the iliac bifurcation. Two further clips (0.1 mm ID) were carefully 
placed around the left and right ovarian arteries. Sham surgery was 
performed as controls, which involved abdominal incision but did 
not involve insertion of any clip on either abdominal aorta or ovarian 
arteries. On GD18, a chronic indwelling catheter was inserted into 
the carotid artery, and on GD19, mean arterial blood pressure was 
recorded in conscious animals.
ERG In Vivo Experimental Protocol
Four experimental groups were used to investigate the effect of ad-
ministration of ERG in the RUPP rat model of preeclampsia. Pregnant 
rats were divided into Sham (n=8), Sham+ERG (n=8) or RUPP (n=8), 
and RUPP+ERG (n=8). ERG was administered at 25 mg/kg per day 
in their drinking water on GD11 until the end of the experiment on 
GD19. The dose for ERG (25 mg/kg per day) was selected based on 
previously published rodent studies using this antioxidant.22,23 ERG 
was provided by Tetrahedron (Paris, France; www.tetrahedron.fr).
Plasma Collection
Blood collected from EDTA vacutainers was centrifuged at 2000g 
and 2400g for 10 minutes at 4°C; plasma was removed and stored at 
−80°C for further analysis.
Urine Analysis
On GD18, each rat was singularly housed in a metabolic cage and 
urine collected overnight. All samples were stored immediately fol-
lowing collection at −80°C. Albumin:creatinine ratios were calcu-
lated after measurement of albumin using an immunoturbidimetric 
test for the quantitative determination of albumin in an OLYMPUS 
AU5832 analyzer and urine creatinine using a kinetic colorimetric 
test (Jaffé method).24 Similarly, protein:creatinine ratios were calcu-
lated after measurement of protein by adding benzethonium chloride, 
which resulted in the formation of a fine suspension, which was then 
quantified turbidimetrically at 525 nm using an OLYMPUS analyzer.
Measurement of Antiangiogenic Protein sFlt-1 by 
ELISA
Circulating sFlt-1 concentration in plasma samples from all exper-
imental groups was quantified by ELISA using a Quantikine sFlt-1 
immunoassay (R&D Systems) as per manufacturers’ instructions.
Isolation of RNA and Real-Time Polymerase Chain 
Reaction Analysis
RNA was extracted from placental tissue using the Trizol method. 
SLC22A4 (ERG transporter) should be replaced with OCTN1 (or-
ganic cation transporter, novel, type 1), SOD1 (superoxide dismutase 
1), SOD2 (superoxide dismutase 2), and UCP-1 (uncoupling protein-1), 
PCG-1α  (peroxisome proliferator activated receptor-γ coactivator 
1α) and Nrf2 (nuclear factor [erythroid-derived 2]–like 2) gene ex-
pression was quantified by real-time polymerase chain reaction using 
StepONE Plus Detection system. Taqman assays (Applied Biosciences) 
and Sybr Green primers were used for quantification. The amounts of 
the target genes were normalized to the geometric mean of internal con-
trol gene 18S and were determined using the comparative 2−ΔΔCT method.
Isometric Myography
In all groups, third-order mesenteric arteries were dissected and 
mounted on a 4-channel wire myograph (Model 610 mol/L Danish 
Myo Technology) containing oxygenated (95% O2 and 5% CO2) phys-
iological salt solution at 37°C. Vessels were normalized to achieve a 
transmural pressure of 100 mmHg using the DMT Normalization soft-
ware. Isometric tension was recorded and displayed using Powerlab 
Chart Software (AD Instruments). The viability of the smooth muscle 
was examined by the addition of a 123-mmol/L KCl solution. After 
physiological salt solution washes, concentration responses were 
performed with thromboxane mimetic U46619 (9,11-dideoxy-
11α,9α-epoxymethanoprostaglandin F2α; 10−9 to 10−5 M) and either 
BK (bradykinin; 10−8 to 10−5 M), acetylcholine (10−8 to 10−5 M), or 
sodium nitroprusside (10−8 to 10−5 M), respectively.25,26
Estimation of Mitochondrial H2O2 in the RUPP 
Model In Vivo
Mitochondrial hydrogen peroxide was measured in vivo using the 
Cayman Chemical Hydrogen Peroxide Ratiometric MaxSpec kit 
based on the MitoB mass spectrometric probe method described pre-
viously.27 Briefly, 75 nmol MitoB in 50 μL saline was administered 
by tail-vein injection to rats in the 4 experimental groups on GD19, 4 
hours before the end of the experiment. At the end of the procedure, 
kidney tissues were dissected out, snap-frozen, and stored at −80°C. 
For mitochondrial H2O2 analysis, kidney tissues were homogenized, 
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spiked with deuterated internal standards, and MitoB, and its product 
MitoP was extracted using acetonitrile/formic acid. MitoB and MitoP 
present in kidney tissue were measured using UPLC Xevo TQD mass 
spectrometer (Waters), and the amounts of MitoP and MitoB in each 
sample were determined relative to a standard curve. The MitoP/B 
ratios for each sample were then calculated.
Statistical Analysis
All data are expressed as mean±SEM or fold change relative to 
control. Analysis was performed using GraphPad Prism, and 
Student t test was applied when comparisons were made between 
2 groups. For analyzing the differences in real-time polymerase 
chain reaction and MitoB/P ratio, a 2-way ANOVA was run fol-
lowed by Bonferroni post hoc test.
Results
ERG Ameliorated RUPP-Induced Hypertension
Mean arterial blood pressure was significantly increased in the 
RUPP group compared with sham group (129±3 versus 117±7 
mm Hg; P=0.05; n=8; Figure 1A). Furthermore, administration 
of ERG significantly reduced mean arterial blood pressure in the 
RUPP rats (129±3 versus 115±4 mm Hg; P=0.01; n=8; Figure 1A). 
Mean arterial blood pressure in sham rats treated with ERG was 
not significantly different from RUPP rats treated with ERG, indi-
cating the beneficial effect of ERG antioxidant in reducing blood 
pressure occurs in response to placental ischemia. There was no 
significant difference in either the microalbumin:creatinine ratio 
(Figure 1B) or the protein:creatinine ratio (Figure 1C) in the 
RUPP group compared with Sham group, nor was there a signif-
icant difference in the microalbumin:creatinine ratio in the RUPP 
rats treated with ERG.
ERG Improves Fetal Weight
Fetal birth weight was significantly decreased in the RUPP 
group compared with the Sham group (1.8±0.04 versus 
2±0.03 g; P=0.0004; Figure 2A). Administration of ERG 
significantly rescued fetal growth restriction in the RUPP 
rats (2±0.03 versus 1.8±0.04 g; P=0.0006; Figure 2A). Pup 
weight was not significantly different between Sham or RUPP 
rats treated with ERG (2±0.03 versus 2±0.03 g; P=0.78; 
Figure 2A), indicating the beneficial effect of ERG in rescuing 
fetal weight during placental ischemia. Placental weights were 
significantly reduced in RUPP group compared with Sham 
group (0.4±0.01 versus 0.5±0.01 g; P=0.002; Figure 2B). 
The administration of ERG had no effect on placental weight 
in the RUPP rats (0.4±0.01 versus 0.4±0.01 g; Figure 2B). 
A significant decrease in pup number was observed in the 
RUPP group compared with Sham group (11±1 versus 14±1; 
P=0.02; Figure 3C). There was no significant difference in 
pup number in RUPP rats treated with ERG relative to RUPP 
rats (13±2 versus 11±1). There was no significant difference 
in the crown-to-rump length of pups (Figure S1 in the online-
only Data Supplement) or abdominal circumference (Figure 
S2) in any of the studied groups. Finally, maternal weight did 
not differ between any of the studied groups (Figure S3).
ERG Reduces Circulating sFlt-1 Levels
There was a significant increase in the circulating soluble 
antiangiogenic mediator sFlt-1 in the RUPP group com-
pared with the sham group (1995±97 versus 1185±349 pg/
mL; P=0.04; Figure 3). Administration of ERG significantly 
decreased circulating sFlt-1 levels in RUPP rats (1367±245 
pg/mL; P=0.04; Figure 3).
Effect of ERG on Vasorelaxation in the RUPP 
Model
Mesenteric arteries from the RUPP group displayed impaired 
vasorelaxation in response to BK when compared with the sham 
group (R
max
: 28±7% versus 52±9%, P=0.01; log Half maximal 
effective concentration EC50: −6.6±0.2 versus −6.8±0.3 mol/L, 
P=0.7; Figure 4A). However, no significant differences were 
seen in the vascular response to the endothelial independent 
vasodilator sodium nitroprusside (R
max
: 78±5% versus 80±5%, 
P=0.36; log EC50: −7.1±0.2 versus −7.2±0.4 mol/L, P=0.9; 
Figure S4) or acetylcholine (R
max
: 83±8% versus 81±6%, 
P=0.1; log EC50: −7.1±0.2 versus −7±0.1 mol/L, P=0.6; 
Figure S5). Treatment with ERG had no significant effect on 
the vasorelaxant responses of mesenteric vessels in response to 
BK (R
max
: 23±5% versus 28±7%, P=0.9; log EC50: −6.7±0.2 
versus −6.8±0.2 mol/L, P=0.7; Figure 4B) or sodium nitroprus-
side (R
max
: 78±6% versus 74±4%, P=0.8; log EC50: −7.1±0.2 
versus −7.2±0.2, P=0.9; Figures S6 and S7) in RUPP rats.
ERG Alters Placental Expression of Markers of 
Mitochondrial ROS-Detoxifying Enzymes
Placental expression of mitochondrial orchestrator PGC-1α 
(peroxisome proliferator-activated receptor-γ coactivator 1α; 
Figure 1.  L-ergothioneine (ERG) attenuates 
blood pressure in reduced uterine perfusion 
pressure (RUPP) rats. RUPP rats (n=8) showed 
(A) significantly elevated mean arterial blood 
pressure (MABP) compared with sham group 
(n=8). ERG (25 mg/kg per d) reduced MABP 
in RUPP rats (n=8). Data are presented as 
mean±SEM. *P<0.05, **P<0.01. B, ERG did not 
alter microalbumin to creatinine ratio (MCR) in 
RUPP rats: administration of ERG (25 mg/kg 
per d) did not significantly affect MCR in RUPP 
rats. C, ERG did not alter protein:creatinine 
ratio in RUPP rats: administration of ERG (25 
mg/kg per d) did not significantly affect MCR in 
RUPP rats.
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1±0.4-fold versus 0.4±0.5-fold; n=8; P=0.01; Figure 5A) and 
mitochondrial ROS-detoxifying enzymes including UCP-1 
(1±0.5-fold versus 0.2±0.5-fold; P=0.04) were significantly 
decreased in the RUPP rats. Nrf2—a transcriptional regulator 
of the mitochondrial antioxidant defence system and coacti-
vated by PGC-1α—was also significantly reduced in the RUPP 
rats (1±0.2-fold versus 0.4±0.4-fold; n=8; P=0.01; Figure 5A). 
Placental expression of SOD1 antioxidant was significantly 
increased (1±0.3-fold versus 1.4±0.3-fold; n=8; P=0.02; 
Figure 5B), whereas mitochondrial SOD2 antioxidant was 
significantly reduced (1±0.3-fold versus 0.6±0.3-fold; n=8; 
P=0.01; Figure 5B) in RUPP rats compared with sham group.
ERG treatment significantly increased placental ex-
pression of PGC-1α (1.7±0.3-fold versus 1±0.5-fold; n=8; 
P=0.02), UCP-1 (4.9±0.6-fold versus 1±0.5-fold; n=8; 
P=0.001), and Nrf2 (1.6±0.3-fold versus 1±0.4-fold; n=8; 
P=0.02; Figure 5A) in RUPP rats. ERG treatment signifi-
cantly increased placental expression of SOD2 in RUPP rats 
(1.5±0.3-fold versus 1±0.3-fold; n=8; P=0.02; Figure 5B). 
ERG treatment significantly increased both SOD1 (3.4±0.4-
fold versus 1±0.8-fold) and SOD2 (1.4±0.3-fold versus 1±0.8-
fold) expression in RUPP rats compared with sham rats. ERG 
treatment also significantly increased placental expression 
of the ERG transporter OCTN1 (organic cation transporter, 
novel, type 1) (1.9±0.3-fold versus 1±0.5-fold) in RUPP rats 
compared with sham rats (Figure 5B).
ERG Reduces Mitochondria-Specific H2O2 
Production in the Kidney
MitoP/B ratio was increased in kidney tissue of RUPP rats com-
pared with the sham group (0.029±0.001 versus 0.024±0.006; 
n=3; P=0.3; Figure 6), indicating for the first time that mito-
chondria-specific H2O2 is increased in vivo as a result of pla-
cental ischemia. MitoP/B ratio was significantly increased in 
kidney tissue between RUPP and Sham rats treated with ERG 
(0.022±0.003 versus 0.017±0.003; n=3; P=0.05; Figure 6). 
Furthermore, pretreatment with ERG significantly reduced 
the MitoP/B ratio in kidney tissue in RUPP rats (0.022±0.003 
versus 0.029±0.001; n=3; P=0.05; Figure 6), establishing that 
ERG reduces mitochondria-specific H2O2 production in vivo.
Discussion
Despite a significant amount of evidence for the pathological role 
of oxidative stress in the development of preeclampsia, clinical 
data from 2 major antioxidant vitamin trials have been nega-
tive.28,29 One possible reason for these negative findings may be 
Figure 2. L-ergothioneine (ERG) improves fetal 
outcomes in reduced uterine perfusion pressure 
(RUPP) rats. RUPP rats (n=8) show reduced 
(A) pup weight and (B) placental weight and 
(C) litter size compared with sham group (n=8). 
Administration of ERG (25 mg/kg per d) improved 
fetal outcome in RUPP rats. Data are presented 
as mean±SEM. *P<0.05, **P<0.01, ***P<0.001.
Figure 3. L-ergothioneine (ERG) reduces 
circulating antiangiogenic factor sFlt-1 (soluble 
fms-like tyrosine kinase-1) in reduced uterine 
perfusion pressure (RUPP) rats: circulating 
levels of sFlt-1 were significantly increased in 
RUPP rats (n=8) compared with sham controls 
(n=8). Administration of ERG significantly 
reduced circulating sFlt-1 levels in RUPP rats. 
Data are presented as mean±SEM. *P<0.05.
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due to the fact these interventions missed the primary intracel-
lular producer of ROS, namely the mitochondria, or because in 
the presence of free or poorly liganded iron, substances such as 
ascorbate are actually pro-oxidant.9 In the present study, ERG—
an amino acid with potent antioxidant properties—attenuated hy-
pertension and rescued fetal growth restriction in the preclinical 
RUPP rat model of preeclampsia, which closely mimics many 
aspects of preeclampsia during human pregnancy. Additionally, 
this study also reported the novel finding of reduced mitochon-
drial H2O2 levels in vivo following ERG administration. This 
work has highlighted that ERG acts as a potent antioxidant that 
ameliorates a number of phenotypic features of preeclampsia in a 
preclinical model of disease and mediated, in part, by the reduc-
tion of mROS. This work consequently proposes the potential of 
ERG as a viable therapeutic for the prevention of preeclampsia.
ERG is a water-soluble amino acid that is derived en-
tirely from dietary sources. It has garnered much attention 
recently as a potential therapeutic intervention,13,30–33 partly 
because of its preferential accumulation within tissues 
undergoing significant oxidative stress. A recent study inves-
tigating the reproductive safety profile of ERG in pregnant 
Sprague Dawley rats established that ERG was well toler-
ated and with no adverse effects on a number of parame-
ters (number of mating days, gestation length, pup viability 
index, or litter parameters).34 Furthermore, ERG treatment 
of diabetic rats significantly improved embryo formation 
and quality.31 Collectively, these data suggest ERG treatment 
may be safe to use in pregnancy and may prevent embryo 
malformations mediated by oxidative stress early in preg-
nancy. Consequently, we decided to administer ERG at an 
early point in pregnancy (GD11) in the preclinical RUPP 
model of preeclampsia.
The therapeutic effects of ERG in response to induced 
tissue damage in models of ischemia-reperfusion injury in 
the liver35 and intestine22 have previously been reported by 
the dampening of markers of oxidative stress and inflamma-
tion. Our novel data using ERG reported a reduction in hy-
pertension and an improvement in fetal weight in response 
to placental ischemia in the preclinical RUPP model of pree-
clampsia, in part, due to regulation of mROS. Recent evidence 
identified a prominent role for mROS in modulating hyperten-
sion.36 Using 2 in vivo murine models of hypertension (Ang 
II [angiotensin II] induced and deoxycorticosterone acetate 
salt), this group established that using a mitochondria-targeted 
antioxidant (Mito-Tempo) alleviated endothelial dysfunction, 
reduced vascular mitochondrial superoxide and subsequent 
hypertension.36 Furthermore, similar to our work, Vaka et al37 
showed in the preclinical RUPP model that placental ischemia 
dysregulated mitochondrial function with elevated mROS and 
identified that treatment with mitochondria-targeted antioxi-
dants attenuated hypertension with improvement in fetal out-
comes in treated RUPP rats.
Figure 4. Impaired vasorelaxation in mesenteric arteries in reduced uterine 
perfusion pressure (RUPP) rats: RUPP rats (n=8) showed significantly 
impaired vasorelaxation in response to BK (bradykinin) compared with 
the sham group (n=8). Administration of L-ergothioneine (ERG) did not 
attenuate the impaired vasorelaxation to BK. Relaxation is calculated as 
a percentage of the maximum contraction and expressed as mean±SEM. 
*P<0.05.
Figure 5. L-ergothioneine (ERG) regulates 
placental expression of mitochondrial ROS-
detoxifying enzymes in reduced uterine 
perfusion pressure (RUPP) rats. (A) Placental 
expression of PGC-1α (peroxisome proliferator-
activated receptor-γ coactivator 1α), UCP-1 
(uncoupling protein-1), and Nrf2 (nuclear 
factor [erythroid-derived 2]–like 2) expression 
were significantly reduced in RUPP rats 
(n=8) compared with sham group (n=8). 
Administration of ERG significantly increased 
placental expression of all these mitochondrial 
markers in RUPP rats. B, Placental expression 
of antioxidant SOD1 (superoxide dismutase 
1) was significantly increased, whereas 
mitochondrial SOD2 (superoxide dismutase 
2) expression was significantly decreased in 
the RUPP group compared with sham group. 
Administration of ERG significantly increased 
mitochondrial antioxidant SOD1 expression 
in RUPP rats compared with sham, while also 
significantly increased SOD2 expression in 
RUPP rats. Administration of ERG significantly 
increased OCTN1 (organic cation transporter, 
novel, type 1) expression in RUPP rats 
compared with sham. Data are presented as 
mean±SEM. *P<0.05, **P<0.01.
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In this study, we found there was no significant increase 
in urinary protein in the RUPP rats compared with sham rats, 
which has also been reported in a recent RUPP study.38 It 
could be proposed that the short duration of gestation in the 
rat decreases the prospect of inflicting severe renal damage to 
routinely detect proteinuria in these rats. Deleterious circulating 
mediators including sFlt-1 are secreted in response to placental 
ischemia and have devastating consequences on the maternal 
vasculature. Furthermore, we previously detected increased lev-
els of mitochondria-specific superoxide production in human 
umbilical vein endothelial cells incubated with plasma from 
women with preeclampsia compared with matched controls and 
nonpregnant controls.39 Additionally, Zsengeller et al40 estab-
lished an inverse correlation between placental sFlt-1 and mi-
tochondrial complex IV, suggesting that sFlt-1 may be harmful 
to mitochondria in preeclampsia. In our study, ERG treatment 
reduced the circulating levels of sFlt-1 in RUPP rats, indicating 
that ERG may preserve mitochondrial function, in part, by re-
ducing the availability of sFlt-1 to induce mitochondrial dam-
age. The reduction in sFlt-1 as a result of ERG treatment did not 
result in a subsequent reduction in maternal vascular dysfunc-
tion in mesenteric arteries of the RUPP rats; however, future 
work could investigate maternal vascular dysfunction in a more 
physiologically relevant vasculature such as the uterine arteries.
The capacity to accurately measure the concentration of 
ROS, in particular mROS in vivo, has proved to be extremely 
challenging, yet is essential in understanding their physiolog-
ical roles in certain diseases. The detection of mROS such 
as superoxide using fluorescent probes can be inferred, with 
certain caveats, by determining the changes in fluorescence 
or ex vivo tissue measurements of electron transport chain 
complexes, but these methods can be less selective and sensi-
tive. One potential alternative is to use exogenous ratiometric 
probes (MitoB) injected into the animal models, which readily 
accumulate in mitochondria of tissues because of its posses-
sion of a triphenylphosphonium cation and which reacts with 
H2O2 in vivo to produce a diagnostic exomarker (MitoP) that 
can be accurately quantified by mass spectrometry.41
In this study, we have shown for the first time that this method 
of measuring mitochondrial H2O2 production in vivo is appli-
cable in a rat model, without any adverse effects on reproductive 
safety. Furthermore, we reported that mitochondrial H2O2 was 
increased in kidney tissue in the RUPP group compared with 
the sham group. This is in agreement with recent work by Vaka 
et al,37 who showed an increase in mROS in kidney tissue in 
the RUPP group by examining electron transport chain activity 
and cellular respiration ex vivo using isolated mitochondria from 
kidney tissues.37 More importantly, treatment with ERG resulted 
in a significant reduction in mitochondria-specific H2O2 produc-
tion in kidney tissue in RUPP rats, indicating that ERG may be 
mediating its therapeutic effects, in part, by directly reducing 
mROS production in the preclinical model of preeclampsia.
PGC-1α is a transcriptional coactivator that orchestrates 
a number of mitochondrial functions including antioxidant 
defense system and oxidative metabolism.42,43 Consequently, 
PGC-1α directs the expression of mitochondrial ROS-
detoxifying enzymes including superoxide dismutases (SOD1 
and SOD2) and UCP-1, which are directly induced by this tran-
scriptional orchestrator and Nrf2 nuclear receptor.44 UCP-1 is 
a mitochondrial transporter with a well-defined role in regulat-
ing adaptive thermogenesis45; more recently, it has been shown 
to mediate inflated mROS production, in part, via mild uncou-
pling.46 Further evidence to support our theory is provided by 
the fact that placental expression of markers of mitochondrial 
ROS-detoxifying enzymes and their transcriptional regulators 
were significantly improved in ERG-treated RUPP rats, in con-
trast to their reduced expression in RUPP rats.
At present, only one study has investigated the pharmacoki-
netics of ERG administration in human subjects.30 ERG was rap-
idly absorbed and retained within the tissue/plasma with relatively 
low urinary excretion (<4% of administered dose). This work was 
further extended by Tang et al, who established that ERG and its 
metabolites are widely distributed in various tissues in male mice 
administered ERG over a range of days. This group also estab-
lished that ERG was highly retained in the body and suggested 
this could be as a result of possible reabsorption by the kidneys.47
This study provides evidence of the therapeutic potential 
of ERG in a preclinical model of preeclampsia. ERG improved 
both hypertension and fetal weight in the RUPP rat model of 
preeclampsia. Furthermore, ERG treatment significantly al-
tered mitochondrial function in both the kidney and placental 
tissue, which may, in part, be responsible for the beneficial 
effects on phenotypic features of preeclampsia in the RUPP 
model. Given its favorable safety profile, its long half-life 
and resistance to auto-oxidation and multiple mechanisms of 
action, not least its ability to regulate mitochondrial function, 
further studies are needed to explicitly define the protective 
mechanisms of ERG in treating preeclampsia in humans.
Figure 6. L-ergothioneine (ERG) reduces 
mitochondria-specific H2O2 levels. Rats 
were injected with MitoB for 4 h, and the 
ratios of MitoP/B were determined by 
Liquid Chromatography with tandem Mass 
Spectrometry. Data are represented as 
mean±SEM of 3 samples per group and 
corrected for ratio. Statistical analysis 
determined by a 2-way ANOVA followed by 
Bonferroni post hoc test was applied.*P<0.05. 
RUPP indicates reduced uterine perfusion 
pressure.
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Perspectives
The causes of preeclampsia have remained an enigma despite 
intense research efforts in recent decades. Consequently, 
effective interventions and treatments remain elusive, and 
currently, there is no effective treatment for preeclampsia. 
Overall, this study provides evidence that exaggerated mROS 
can play a pathological role in the development of hyper-
tension in response to placental ischemia in a preclinical rat 
model of preeclampsia. Additionally, this study demonstrates 
that ERG—a nutraceutical antioxidant—ameliorates some 
of the phenotypic features of preeclampsia in a preclinical 
model of disease, in part, by the reduction of mROS. This 
work opens a new avenue of investigations for new thera-
peutic options for preeclampsia.
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What Is New?
• There is growing evidence implicating mitochondrial dysfunction in the 
pathophysiology of preeclampsia.
• The nutraceutical antioxidant L-ergothioneine reduces blood pressure 
and rescues fetal growth restriction in the reduced uterine perfusion 
pressure preclinical model of preeclampsia.
• Using a novel ratiometric mass spectrometry probe, we established that 
L-ergothioneine exerts its therapeutic effects, in part, by reducing the 
renal production of mitochondria-specific H
2
O
2
.
What Is Relevant?
• There is overwhelming evidence for deleterious role of exaggerated ox-
idative stress in the pathophysiology of preeclampsia, yet clinical trials 
of antioxidant interventions were not clinically effective in treating this 
disease.
• One potential explanation is that these antioxidants may have missed the 
intracellular mitochondrial reactive oxygen species production.
• This study provides further evidence that therapies targeting mitochon-
dria are an exciting new avenue of investigation for the treatment of 
preeclampsia.
Summary
L-ergothioneine is a water-soluble amino acid with potent anti-
oxidant properties. L-ergothioneine alleviates the clinical charac-
teristics of preeclampsia, in part, via regulation of mitochondria-
specific reactive oxygen species production in the reduced uterine 
perfusion pressure rat model of preeclampsia. Intriguingly, L-ergo-
thioneine has been shown to have an encouraging safety profile in 
recent human studies, which further adds to its potential as a novel 
viable therapeutic for the prevention of preeclampsia.
Novelty and Significance
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